Ethyl 2-[6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethyl-1-benzofuran-3-yl]acetate | 463927-56-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Ethyl 2-[6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethyl-1-benzofuran-3-yl]acetate
• 英文别名: ethyl 2-[6-(4-hydroxy-3-propan-2-ylphenoxy)-5,7-dimethyl-1-benzofuran-3-yl]acetate
• CAS: 463927-56-2
• 化学式: C₂₃H₂₆O₅
• 分子量: 382.456
• InChiKey: IYSVPLSYDUYFLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  68.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Ethyl 2-[6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethyl-1-benzofuran-3-yl]acetate 在 sodium hydroxide 作用下， 以72%的产率得到2-[6-(4-Hydroxy-3-propan-2-ylphenoxy)-5,7-dimethyl-1-benzofuran-3-yl]acetic acid
  参考文献：
  名称：

  Novel heterocyclic thyromimetics. Part 2

  摘要：

  Novel heterocyclic thyromimetics are presented carrying carboxy-substituted benzofurans or sulfur containing heterocycles, as replacements for the amino acid side chain of T3. Potent agonists were identified in both series. SAR trends are examined and found to be mostly consistent with previously published thyromimetics. The lack of isoform selectivity demonstrated with isoform-selective transient THR transfection assays has been confirmed by corresponding in vivo studies. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.085
• 作为产物：
  描述：

  2-(6-Hydroxy-5,7-dimethyl-1-benzofuran-3-yl) acetic acid 在 三氯化铝 、 copper bronze 、 硫酸 、 三乙胺 、 乙硫醇 作用下， 以 二氯甲烷 为溶剂， 反应 22.0h， 生成 Ethyl 2-[6-(4-hydroxy-3-isopropylphenoxy)-5,7-dimethyl-1-benzofuran-3-yl]acetate
  参考文献：
  名称：

  Novel heterocyclic thyromimetics. Part 2

  摘要：

  Novel heterocyclic thyromimetics are presented carrying carboxy-substituted benzofurans or sulfur containing heterocycles, as replacements for the amino acid side chain of T3. Potent agonists were identified in both series. SAR trends are examined and found to be mostly consistent with previously published thyromimetics. The lack of isoform selectivity demonstrated with isoform-selective transient THR transfection assays has been confirmed by corresponding in vivo studies. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.085

文献信息

• Benzofuran derivatives
  申请人：——

  公开号：US20040220415A1

  公开（公告）日：2004-11-04

  The invention relates to novel benzofuran derivatives, to processes for preparing them and to their uses in medicaments.

  本发明涉及新型苯并呋喃衍生物，其制备方法以及在药物中的应用。
• BENZOFURAN-DERIVATE
  申请人：Bayer HealthCare AG

  公开号：EP1373239A1

  公开（公告）日：2004-01-02
• US7015246B2
  申请人：——

  公开号：US7015246B2

  公开（公告）日：2006-03-21
• [DE] BENZOFURAN-DERIVATE<br/>[EN] BENZOFURAN DERIVATIVES<br/>[FR] DERIVES DU BENZOFURANNE
  申请人：BAYER AG

  公开号：WO2002079181A1

  公开（公告）日：2002-10-10

  Die Erfindung behandelt substituierte Benzofuranderivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Azneimittel zur Behandlung von Alzheimer, Herz-/Kreislauf Erkrankungen bzw. Diabetes. Die Wirksamkeit der Verbindungen ist assoziiert mit einer Serumcholesterin absenkenden Wirkung. Formel (I), im welcher Z für O, S, SO, SO2, CH2, CHF, CF2 oder für NR8 steht, worin R8 Wasserstoff oder (C¿1?-C4)-Alkyl bedeutet, R?5¿ zusammen mit den beiden Kohlenstoffatomen des Phenylrings einen gegebenenfalls einfach oder zweifach, gleich oder verschieden substituierten, gesättigten oder ungesättigten Furanring bildet, R7 für Wasserstoff oder für Kation oder eine Gruppe steht, die unter physiologischen Bedingungen unter Bildung einer OH-Funktion abgespalten werden kann, wie vorzugsweise Alkyl oder Acetyl.
• Novel heterocyclic thyromimetics. Part 2
  作者：Helmut Haning、Ulrich Mueller、Gunter Schmidt、Carsten Schmeck、Verena Voehringer、Axel Kretschmer、Hilmar Bischoff

  DOI：10.1016/j.bmcl.2007.04.085

  日期：2007.7

  Novel heterocyclic thyromimetics are presented carrying carboxy-substituted benzofurans or sulfur containing heterocycles, as replacements for the amino acid side chain of T3. Potent agonists were identified in both series. SAR trends are examined and found to be mostly consistent with previously published thyromimetics. The lack of isoform selectivity demonstrated with isoform-selective transient THR transfection assays has been confirmed by corresponding in vivo studies. (C) 2007 Elsevier Ltd. All rights reserved.